IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced that LevPharm Ltd. of Israel has received
regulatory approval allowing the company to commence marketing and distributing
Innovotech's bioFILM PA(TM) test to hospitals possessing Cystic Fibrosis units
within Israel. The marketing licence is valid for one year and will be extended
subject to clinical outcomes and physician's recommendations (regular Ministry
of Health procedure).


"This is the first approval of bioFILM PA(TM) outside of Canada and represents
an acceptance of the need for a diagnostic capable of testing organisms in a
biofilm state," said Ken Boutilier, President and CEO of Innovotech Inc. "It
provides an opportunity for doctors to treat Israeli patients with effective
antibiotics that are tailored to their personal chronic infections. These
patients have the potential to recover more quickly, while saving the health
care system money, and bacteria will have less chance to develop resistance.
Biofilms are the cause of virtually all chronic bacterial infections and are
notoriously hard to eradicate. Use of biofilm PA(TM) will result in better
treatment choices right from the start."


The current market capacity in Israel for bioFILM PA(TM) is estimated to be over
3,000 tests per year.


bioFILM PA(TM) is the first diagnostic test to assist physicians in the
selection of the most effective combination antibiotic treatment of patients
with biofilm-based Pseudomonas aeruginosa infections.


Based on Innovotech's proprietary technology, the company is currently
developing companion products to bioFILM PA(TM) to assist physicians in the
selection of the most effective antibiotic treatment for infections caused by
both gram-positive and gram-negative bacteria. In a biofilm state, these
bacteria are responsible for the majority of all chronic bacterial infections.


Pseudomonas aeruginosa is a common bacterium responsible for many hospital
acquired infections including ventilator-associated pneumonia and those found in
patients with burns and wounds. It is also one of the major causes of lung
infections in individuals with Cystic Fibrosis.


Over eighty percent of microbial infections in the body are caused by organisms
in a biofilm state. Biofilm infections are known to be up to 1,000 times more
resistant to antibiotics than the same organism in a free-floating state, which
demonstrates why it is so critical to identify effective treatments early, such
as through the bioFILM PA(TM) test.


About Innovotech Inc. 

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. There are
currently no antibiotics, disinfectants, diagnostics or regulatory standards
designed specifically for biofilm-forming organisms. 


Innovotech currently has one commercial product, bioFILM PA(TM), and one
product, Agress(R), in advanced stages of development. bioFILM PA(TM) is the
first diagnostic kit to assist physicians in the selection of the most effective
combination antibiotic treatment of patients with biofilm-based chronic lung
infections and Agress(R) is a unique, environmentally friendly seed treatment
and plant spray designed to protect crops against both bacterial and fungal
infections.


About LevPharm Ltd. 

LevPharm Ltd. is a privately owned Israeli pharmaceutical company focusing on
marketing and distribution of pharmaceuticals and medical devices primarily in
the area of pulmonary and CNS diseases Through their long experience in this
market, the professionals at LevPharm focus on building relationships with
clinicians and institutions nation-wide. LevPharm currently represents
international pharmaceutical and medical device firms in Israel and is actively
seeking to expand this portfolio .www. levpharm.com


This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024